|LETTERS TO THE EDITOR
|Year : 2019 | Volume
| Issue : 2 | Page : 269-270
Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction
Remya Rajan, Kripa Elizabeth Cherian, Nitin Kapoor, Thomas V Paul
Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India
|Date of Web Publication||21-May-2019|
Thomas V Paul
Department of Endocrinology, Christian Medical College, Vellore - 632 004, Tamil Nadu
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Rajan R, Cherian KE, Kapoor N, Paul TV. Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction. Indian J Endocr Metab 2019;23:269-70
|How to cite this URL:|
Rajan R, Cherian KE, Kapoor N, Paul TV. Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction. Indian J Endocr Metab [serial online] 2019 [cited 2021 May 7];23:269-70. Available from: https://www.ijem.in/text.asp?2019/23/2/269/258693
We report a case of primary hyperparathyroidism (PHPT) with severe hypercalcemia (15 mg/dL) in the background of renal dysfunction, in whom denosumab (60 mg subcutaneously) was used to lower the calcium levels prior to surgery. Our patient was a 60-year-old gentleman who presented with chronic kidney disease and with medullary nephrocalcinosis (estimated Glomerular filtration rate (GFR) of 21.35 mL/min/1.73 m2). His albumin corrected serum calcium at presentation was 15.28 mg/dL and intact PTH was 1,850 pg/mL (N = 8–50). He was treated with saline diuresis and parenteral salmon calcitonin with which calcium declined to 12.6 mg/dL. However, after 72 h, his serum calcium levels increased and remained >13 mg/dL. Further, to manage the refractory hypercalcemia in the background of kidney disease, we chose denosumab, a RANKL inhibitor, over bisphosphonates due to low GFR. Following administration of denosumab, his calcium level reduced to 10.8 mg/dL and he underwent focussed parathyroidectomy 5 days later. After curative parathyroid surgery, his calcium remained normal and there was no evidence of hungry bone syndrome.
Though bisphosphonates are widely used and approved for the treatment of hypercalcemia, the risk of potential nephrotoxicity precludes its use in those with renal impairment. Although calcimimetic like cinacalcet has been utilized in PHPT, its impact on reducing calcium is not usually immediate and worsening of nephrocalcinosis has been reported in literature. Denosumab is an option in such patients and in those with hypercalcemia that is refractory to bisphosphonates. Denosumab interferes with RANKL signaling and thereby inhibits bone resorption. Unlike bisphosphonates, it is not cleared by the kidney, and hence, there is no restriction of its use in patients with chronic kidney disease. Though Denosumab has been approved and used for hypercalcemia of malignancy, there are limited case reports on its use in patients with refractory hypercalcemia secondary to PHPT prior to surgery. Though the median time to response (time taken to lower calcium to <11.5 mg/dL) for Denosumab has been described as 9 days (7–10 days), in our patient, calcium decreased by day 3. In view of its renal safety and quick action, it is a potential drug for lowering calcium levels especially in those with renal impairment.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
US Food and Drug Administration. FDA drug safety communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm
. [Last accessed on 2012 Feb 09].
Cetani F, Saponaro F, Marcocci C. Non-surgical management of primary hyperparathyroidism, Best Practice & Research Clinical Endocrinology & Metabolism 2018;32:821-35. Available from: https://doi.org/10.1016/j.beem
Moen MD, Keam SJ. Denosumab: A review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011;28:63-82.
Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk 2014;14:e207.
Pugliese F, de Martino D, Scillitani A, Carnevalle V. Denosumab as a bridge to surgery in patients with primary hyperparathyroidism, severe hypercalcemia and renal impairment. Curr Trends Endocrinol 2016;8:41-4.
Thosani S, Hu MI. Denosumab: A new agent in the management of hypercalcemia of malignancy. Future Oncol 2015;11:2865-71.